Tirzepatide in Type 1 Diabetes: Does It Reduce Daily Insulin Needs?
Study evaluating tirzepatide as add-on therapy in type 1 diabetes assessed its effect on total daily insulin dose, exploring whether GLP-1/GIP agonism can reduce insulin requirements in T1D.
Quick Facts
What This Study Found
Study assessed tirzepatide's ability to reduce total daily insulin dose in T1D adults, exploring GLP-1/GIP agonism as insulin-sparing therapy.
Key Numbers
Not detailed in available abstract — study focused on total daily insulin dose changes and glycemic control measures.
How They Did This
Clinical evaluation of tirzepatide as add-on to insulin therapy in adults with T1D. Assessed changes in total daily insulin dose, HbA1c, weight, and safety.
Why This Research Matters
T1D patients take insulin for life but face constant challenges with weight gain and hypoglycemia. If tirzepatide can reduce insulin needs, it addresses both problems simultaneously.
The Bigger Picture
GLP-1 drugs were originally avoided in T1D, but growing evidence shows they can be safe and beneficial as add-on therapy. Tirzepatide's dual GLP-1/GIP mechanism may offer additional benefits for T1D patients beyond what single GLP-1 drugs provide.
What This Study Doesn't Tell Us
T1D patients always need some insulin. GLP-1/GIP drugs do not replace insulin in T1D. Risk of DKA if insulin is reduced too aggressively. Not FDA-approved for T1D.
Questions This Raises
- ?How much can tirzepatide safely reduce insulin doses in T1D?
- ?Does reduced insulin dose translate to fewer hypoglycemic episodes?
- ?Should tirzepatide be pursued for FDA approval in T1D?
Trust & Context
- Key Stat:
- Less insulin needed? Tirzepatide evaluated as insulin-sparing add-on therapy in T1D — potentially reducing daily insulin dose while improving weight and control
- Evidence Grade:
- Moderate evidence: clinical evaluation of tirzepatide in T1D for insulin dose reduction.
- Study Age:
- Published in 2025. Explores an off-label but increasingly researched application.
- Original Title:
- Evaluating the Effect on Total Daily Insulin Dose in Adult Patients with Type 1 Diabetes Managed with Metformin and/or GLP-1 or GLP-1/GIP Receptor Agonists.
- Published In:
- Innovations in pharmacy, 16(1) (2025)
- Authors:
- Ahmed, Mayeesha, Pierson, Emily, Webster, Molly
- Database ID:
- RPEP-09802
Evidence Hierarchy
Frequently Asked Questions
Can T1D patients use tirzepatide?
It's being studied but not yet approved for T1D. Some endocrinologists prescribe it off-label alongside insulin. It may reduce insulin needs and help with weight management, but T1D patients must never stop insulin entirely.
How would tirzepatide help in type 1 diabetes?
By improving insulin sensitivity and promoting weight loss, tirzepatide may allow T1D patients to use less insulin. Less insulin means fewer hypoglycemic episodes and less insulin-related weight gain — two major T1D challenges.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09802APA
Ahmed, Mayeesha; Pierson, Emily; Webster, Molly. (2025). Evaluating the Effect on Total Daily Insulin Dose in Adult Patients with Type 1 Diabetes Managed with Metformin and/or GLP-1 or GLP-1/GIP Receptor Agonists.. Innovations in pharmacy, 16(1). https://doi.org/10.24926/iip.v16i1.6450
MLA
Ahmed, Mayeesha, et al. "Evaluating the Effect on Total Daily Insulin Dose in Adult Patients with Type 1 Diabetes Managed with Metformin and/or GLP-1 or GLP-1/GIP Receptor Agonists.." Innovations in pharmacy, 2025. https://doi.org/10.24926/iip.v16i1.6450
RethinkPeptides
RethinkPeptides Research Database. "Evaluating the Effect on Total Daily Insulin Dose in Adult P..." RPEP-09802. Retrieved from https://rethinkpeptides.com/research/ahmed-2025-evaluating-the-effect-on
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.